- Report
- June 2024
- 256 Pages
Global
From €6673EUR$6,995USD£5,683GBP
- Report
- May 2024
- 640 Pages
Global
From €4578EUR$4,799USD£3,899GBP
- Report
- November 2023
- 321 Pages
Global
From €4004EUR$4,197USD£3,410GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,414USD£1,895GBP
- Report
- May 2024
- 420 Pages
Global
From €2676EUR$2,805USD£2,279GBP
€3148EUR$3,300USD£2,681GBP
- Report
- December 2023
- 220 Pages
Global
From €2676EUR$2,805USD£2,279GBP
€3148EUR$3,300USD£2,681GBP
- Report
- October 2023
- 420 Pages
Global
From €2351EUR$2,465USD£2,003GBP
€2766EUR$2,900USD£2,356GBP
- Report
- October 2023
- 420 Pages
Global
From €2351EUR$2,465USD£2,003GBP
€2766EUR$2,900USD£2,356GBP
- Report
- March 2024
- 199 Pages
Global
From €3219EUR$3,374USD£2,741GBP
€3576EUR$3,749USD£3,046GBP
- Report
- May 2024
- 192 Pages
Global
From €3219EUR$3,374USD£2,741GBP
€3576EUR$3,749USD£3,046GBP
- Report
- March 2024
- 195 Pages
Global
From €3219EUR$3,374USD£2,741GBP
€3576EUR$3,749USD£3,046GBP
- Report
- September 2023
- 249 Pages
Global
From €4800EUR$5,208USD£3,950GBP
- Report
- September 2023
- 98 Pages
Global
From €5676EUR$5,950USD£4,834GBP
- Report
- June 2023
- 150 Pages
Global
From €5676EUR$5,950USD£4,834GBP
- Report
- February 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,062GBP
- Report
- February 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,062GBP
- Report
- November 2023
- 175 Pages
Global
From €4770EUR$5,000USD£4,062GBP
- Report
- November 2023
- 175 Pages
Global
From €4770EUR$5,000USD£4,062GBP
- Report
- February 2024
- 250 Pages
Global
From €4770EUR$5,000USD£4,062GBP
- Report
- December 2023
- 200 Pages
Global
From €4770EUR$5,000USD£4,062GBP
CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more